MK-571 (sodium)

CAT: 0804-HY-19989A-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-19989A-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1) . MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release[1][2][3].
CAS Number
[115103-85-0]
Product Name Alternative
L-660711 (sodium)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Leukotriene Receptor; LPL Receptor; P-glycoprotein
Type
Reference compound
Related Pathways
GPCR/G Protein; Membrane Transporter/Ion Channel
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/mk-571-sodium.html
Concentration
10mM
Purity
99.75
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(O[Na])CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O
Molecular Formula
C26H26ClN2NaO3S2
Molecular Weight
537.07
Precautions
H302, H315, H319, H335
References & Citations
4
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
LTD4/CysLT1; LTE4
Citation 01
Arch Toxicol. 2020 Nov;94 (11) :3799-3817.|Biomed Pharmacother. 2018 Oct:106:1563-1569.|Brain Res Bull. 2022 Oct 15:189:69-79.|Cancer Res Commun. 2024 Apr 9;4 (4) :1024-1040.|Cell. 2023 Dec 7;186 (25) :5500-5516.e21.|CNS Neurosci Ther. 2023 Jan;29 (1) :445-457.|Commun Biol. 2024 May 23;7 (1) :621.|Eberhard Karls Universität Tübingen. 2022 Feb.|Eur J Drug Metab Pharmacokinet. 2022 Mar;47 (2) :279-289.|Eur J Drug Metab Pharmacokinet. 2024 Sep;49 (5) :609-617.|Eur J Pharm Sci. 2023 May 1:184:106414.|Free Radic Biol Med. 2024 Jun 19:S0891-5849 (24) 00531-8.|Int J Nanomedicine. 2019 Nov 27;14:9217-9234.|J Appl Toxicol. 2024 Nov;44 (11) :1725-1741.|Pharmaceutics. 2024 May 29;16 (6) :731.|Pharmacol Res Perspect. 2022 Feb;10 (1) :e00928.|Regul Toxicol Pharmacol. 2019 Nov:108:104449.|Sci Adv. 2024 Dec 13;10 (50) :eadq4274.|Toxicol Lett. 2020 Jul 1;327:9-18.|Xenobiotica. 2020 Mar;50 (3) :354-362.|3 Biotech. 2025 Apr;15 (4) :72.|Adv Sci (Weinh) . 2025 Aug 4:e04680.|Biomed Pharmacother. 2020 Sep;129:110506.|Cell Death Discov. 2024 Aug 14;10 (1) :364.|Drug Metab Dispos. 2025 Sep 24.|J Drug Deliv Sci Technol. 2025 May.|J Pharm Biomed Anal. 2020 Sep 10;189:113441.|Nat Commun. 2023 Sep 19;14 (1) :5709.|Toxicology. 2025 Jun 3:154210.|Viruses. 2019 Apr 24;11 (4) :378.

Popular Products